# Low-Dose Sublingual Ketamine for the Treatment of Raynaud's Phenomenon

## TL;DR

A woman with Raynaud's phenomenon experienced symptom improvement using low-dose sublingual ketamine, suggesting it may be a potential treatment.

## Contribution

This case report introduces low-dose sublingual ketamine as a novel treatment option for Raynaud's phenomenon.

## Key findings

- A patient with treatment-resistant depression and Raynaud's phenomenon showed significant symptom improvement with low-dose sublingual ketamine.
- Ketamine's vasodilatory properties may enhance blood flow and reduce Raynaud's symptoms.
- The case suggests ketamine could be a safe and inexpensive treatment for Raynaud's phenomenon.

## Abstract

Raynaud's phenomenon is a vascular disorder characterized by episodic vasospasm of small arteries, primarily affecting the hands and feet. Standard treatment strategies typically include lifestyle modifications to avoid cold exposure and stress, alongside pharmacological interventions aimed at increasing blood flow and reducing vascular constriction. Ketamine, an FDA-approved anesthetic since 1970, exhibits analgesic and vasodilatory properties that may enhance perfusion. This case report describes a woman with primary Raynaud's phenomenon whose symptoms improved significantly during treatment with low-dose sublingual ketamine prescribed for treatment-resistant depression. Further research into the use of this safe and inexpensive medicine as a treatment for Raynaud's phenomenon is recommended.